Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages IRVING, Texas --(BUSINESS WIRE)--Nov. 12, 2024-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive

IRVING, Texas --(BUSINESS WIRE)--Oct. 29, 2024-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter

Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance IRVING, Texas --(BUSINESS WIRE)--Aug. 8, 2024-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery

IRVING, Texas --(BUSINESS WIRE)--Jul. 25, 2024-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter

IRVING, Texas --(BUSINESS WIRE)--Jun. 20, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with

Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second half growth IRVING, Texas --(BUSINESS WIRE)--May 7, 2024-- Biote (NASDAQ: BTMD), a leading solutions

Company to repurchase all of Founder’s 18.4 million shares at $4.17 per share IRVING, Texas --(BUSINESS WIRE)--Apr. 29, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and

IRVING, Texas --(BUSINESS WIRE)--Apr. 23, 2024-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter

Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders’ shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance,

IRVING, Texas --(BUSINESS WIRE)--Feb. 27, 2024-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter